Madrigal Press Releases

Madrigal Pharmaceuticals

Skip to content

About Us
Our Approach
News Room
Investors

News Room

Headlines
Presentations
NASH Experts Webcasts
Media Contact

Headlines

Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights
February 25, 2021

Madrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital ExperienceTM, The American Association for the Study of Liver Diseases Meeting November 13, 2020, Including NASH Expert Insights on the Ongoing Open Label Arm of Resmetirom 52-Week Phase 3 MAESTRO- NAFLD-1 Trial
November 13, 2020

Madrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and Highlights
November 5, 2020

Press Release History

©2020 Madrigal Pharmaceuticals, Inc. All rights reserved.

- About Us
- Our Approach
- News Room
- Investors
- Contact Us
- Legal
- Privacy
- Cookies

Madrigal Pharmaceuticals
200 Barr Harbor Drive Suite 200 West Conshohocken, PA 19428

Madrigal Clinical Trials

Resmetirom is an investigational therapy and has not been approved by the FDA (or any other regulatory authority). Resmetirom is only available for use in a clinical trial setting (ClinicalTrials.gov NCT03900429 and NCT04197479)

Website Developed by Alan Leff Associates, Inc.